No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy

Peng Yuan, Li Liu, Chen Wu, Rong Zhong, Dianke Yu, Jing Wu, Yihua Xu, Shaofa Nie, Xiaoping Miao, Yan Sun, Binghe Xu, Dongxin Lin

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Purpose: Genetic polymorphisms in DNA repair genes are thought to represent important determinants of platinum drug efficacy. The current study investigated whether single nucleotide polymorphisms (SNPs) in the X-ray repair cross complementing protein 1 (XRCC1) gene are associated with survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Results: During the median 26.5 months of follow-up, 159 deaths occurred. Regarding XRCC1 Arg194Trp, Arg280His and Arg399Gln genotypes, no significant effects on survival were observed, although the 280Arg/His genotype was associated with a borderline-significant higher median survival time (20.0 months for Arg/His versus 16.0 months for Arg/Arg; p = 0.131). Moreover, no significant association of haplotypes with survival was found. Experimental design: A total of 199 platinum-treated patients with stage III-IV NSCLC were recruited. Overall survival (OS) and progression-free survival (PFS) according to genotypes and haplotypes were analyzed using Kaplan-Meier method and assessed by log-rank test. Hazard ratios (HRs) were calculated using Cox proportional hazards models by adjusting for clinical factors. Conclusions: This study showed no influence of the XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms on survival in advanced NSCLC patients with platinum-based chemotherapy.

Original languageEnglish
Pages (from-to)854-859
Number of pages6
JournalCancer Biology and Therapy
Volume10
Issue number9
DOIs
StatePublished - Nov 1 2010

Keywords

  • Haplotype
  • Non-small-cell lung cancer
  • Overall survival
  • Platinum drug
  • Polymorphism
  • Progression-free survival
  • XRCC1

Fingerprint

Dive into the research topics of 'No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy'. Together they form a unique fingerprint.

Cite this